Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diabetes Drug Is Linked With Bladder Cancer Risk

Diabetes Drug Is Linked With Bladder Cancer Risk Recent research links the diabetes drug pioglitazone with an increased risk of bladder cancer. The nested case-control study analyzed data from 115 727 patients in the United Kingdom who were newly treated with diabetes drugs between 1988 and 2009. Researchers reported an 83% increased risk of bladder cancer in those who had ever taken pioglitazone, which translates into a rate of 74 cases per 100 000 person-years. Even though that's similar to the rate among people at least 65 years old in the United Kingdom—73 per 100 000 person-years—the study participants were younger (mean age, 64.1 years) and so at less risk of developing bladder cancer. Investigators also found that in patients taking the drug for 2 years or longer, the bladder cancer rate was 88 cases per 100 000 person-years and 137 per 100 000 in patients with a cumulative dose totaling 28 000 mg or more (Azoulay L et al. BMJ. doi: 10.1136/bmj.e3645 [published online May 31, 2012]). Pioglitazone, which belongs to the thiazolidinedione class of drugs, helps control blood glucose levels in patients with type 2 diabetes. Another diabetes drug in the same class, rosiglitazone, was not linked in the study with an increased bladder cancer risk. The study's authors wrote that pioglitazone's association with bladder cancer may have been underestimated in previous observational studies. They noted that physicians, patients, and regulatory agencies “should be aware of this association when assessing the overall risks and benefits of this therapy.” In 2011, the US Food and Drug Administration added a label warning of the increased bladder cancer risk associated with pioglitazone. Authorities in France removed the drug from the market last year. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Diabetes Drug Is Linked With Bladder Cancer Risk

JAMA , Volume 307 (24) – Jun 27, 2012

Diabetes Drug Is Linked With Bladder Cancer Risk

Abstract

Recent research links the diabetes drug pioglitazone with an increased risk of bladder cancer. The nested case-control study analyzed data from 115 727 patients in the United Kingdom who were newly treated with diabetes drugs between 1988 and 2009. Researchers reported an 83% increased risk of bladder cancer in those who had ever taken pioglitazone, which translates into a rate of 74 cases per 100 000 person-years. Even though that's similar to the rate among people at least 65 years old...
Loading next page...
 
/lp/american-medical-association/diabetes-drug-is-linked-with-bladder-cancer-risk-iVL1U1WWlH

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 2012 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2012.7131
Publisher site
See Article on Publisher Site

Abstract

Recent research links the diabetes drug pioglitazone with an increased risk of bladder cancer. The nested case-control study analyzed data from 115 727 patients in the United Kingdom who were newly treated with diabetes drugs between 1988 and 2009. Researchers reported an 83% increased risk of bladder cancer in those who had ever taken pioglitazone, which translates into a rate of 74 cases per 100 000 person-years. Even though that's similar to the rate among people at least 65 years old in the United Kingdom—73 per 100 000 person-years—the study participants were younger (mean age, 64.1 years) and so at less risk of developing bladder cancer. Investigators also found that in patients taking the drug for 2 years or longer, the bladder cancer rate was 88 cases per 100 000 person-years and 137 per 100 000 in patients with a cumulative dose totaling 28 000 mg or more (Azoulay L et al. BMJ. doi: 10.1136/bmj.e3645 [published online May 31, 2012]). Pioglitazone, which belongs to the thiazolidinedione class of drugs, helps control blood glucose levels in patients with type 2 diabetes. Another diabetes drug in the same class, rosiglitazone, was not linked in the study with an increased bladder cancer risk. The study's authors wrote that pioglitazone's association with bladder cancer may have been underestimated in previous observational studies. They noted that physicians, patients, and regulatory agencies “should be aware of this association when assessing the overall risks and benefits of this therapy.” In 2011, the US Food and Drug Administration added a label warning of the increased bladder cancer risk associated with pioglitazone. Authorities in France removed the drug from the market last year.

Journal

JAMAAmerican Medical Association

Published: Jun 27, 2012

Keywords: bladder cancer,antidiabetics

There are no references for this article.